Dataset Information

Tumor biology and immune infiltration define primary liver cancer subsets linked to overall survival after immunotherapy.

ABSTRACT: Primary liver cancer is a rising cause of cancer deaths in the US. Although immunotherapy with immune checkpoint inhibitors induces a potent response in a subset of patients, response rates vary among individuals. Predicting which patients will respond to immune checkpoint inhibitors is of great interest in the field. In a retrospective arm of the National Cancer Institute Cancers of the Liver: Accelerating Research of Immunotherapy by a Transdisciplinary Network (NCI-CLARITY) study, we use archived formalin-fixed, paraffin-embedded samples to profile the transcriptome and genomic alterations among 86 hepatocellular carcinoma and cholangiocarcinoma patients prior to and following immune checkpoint inhibitor treatment. Using supervised and unsupervised approaches, we identify stable molecular subtypes linked to overall survival and distinguished by two axes of aggressive tumor biology and microenvironmental features. Moreover, molecular responses to immune checkpoint inhibitor treatment differ between subtypes. Thus, patients with heterogeneous liver cancer may be stratified by molecular status indicative of treatment response to immune checkpoint inhibitors.

SUBMITTER: Budhu A

PROVIDER: S-EPMC10313915 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Tumor biology and immune infiltration define primary liver cancer subsets linked to overall survival after immunotherapy.

Budhu Anuradha A Pehrsson Erica C EC He Aiwu A Goyal Lipika L Kelley Robin Kate RK Dang Hien H Xie Changqing C Monge Cecilia C Tandon Mayank M Ma Lichun L Revsine Mahler M Kuhlman Laura L Zhang Karen K Baiev Islam I Lamm Ryan R Patel Keyur K Kleiner David E DE Hewitt Stephen M SM Tran Bao B Shetty Jyoti J Wu Xiaolin X Zhao Yongmei Y Shen Tsai-Wei TW Choudhari Sulbha S Kriga Yuliya Y Ylaya Kris K Warner Andrew C AC Edmondson Elijah F EF Forgues Marshonna M Greten Tim F TF Wang Xin Wei XW

Cell reports. Medicine 20230523 6

Primary liver cancer is a rising cause of cancer deaths in the US. Although immunotherapy with immune checkpoint inhibitors induces a potent response in a subset of patients, response rates vary among individuals. Predicting which patients will respond to immune checkpoint inhibitors is of great interest in the field. In a retrospective arm of the National Cancer Institute Cancers of the Liver: Accelerating Research of Immunotherapy by a Transdisciplinary Network (NCI-CLARITY) study, we use arch ...[more]

PMID: 37224815

Similar Datasets

Project description:Importance:Melanoma treatment has been revolutionized with the development of immune-based therapies that offer durable clinical responses in a subset of patients. Clinical outcomes after treatment by immunotherapy can be influenced by the host's immune system. The immune system is modified with age by age-related immune dysfunction. Objective:To evaluate if age influences clinical outcome and immune adverse events in patients treated by immunotherapy for metastatic melanoma. Design, Setting, and Participants:This was a single-center cohort analysis in patients treated with immunotherapy for metastatic melanoma between January 2007 and February 2016, in the Lyon Sud Hospital, France. A total of 92 patients with metastatic melanoma treated with ipilimumab, nivolumab, or pembrolizumab were retrospectively analyzed. Main Outcomes and Measures:Overall survival, progression-free survival, and immune-related adverse events were evaluated for each treatment line according to the patients' age. Results:A total of 92 patients were eligible and included in this study for a total of 120 lines of treatment. Fifty-four patients were included in the cohort that was 65 years or younger (24 [44%] were female; mean [SD] age, 48.1 [12.5] years), and 38 patients were included in the cohort that was older than 65 years (12 [34%] were female; mean [SD] age, 74.8 [6.9] years). Mean follow-up duration starting at treatment initiation was 12.5 months. Patients older than 65 years treated with immunotherapy had a better mean progression-free survival (4.8 vs 3.4 months; P = .04) and overall survival (not reached vs 10.1 months; P = .009) than younger patients in univariate analysis, and after adjusting on prognosis covariates. This was particularly true with patients treated with anti-programmed cell death protein 1. Common immune-related adverse effects were similar in both cohorts. Conclusions and Relevance:Age might be associated with a better clinical outcome after treatment with immunotherapy in the real-life setting. In our cohort, older patients did not have more immune-related adverse events. Further studies are warranted to confirm our results and describe the underlying mechanisms involved.

Dataset Information

Tumor biology and immune infiltration define primary liver cancer subsets linked to overall survival after immunotherapy.

Publications

Tumor biology and immune infiltration define primary liver cancer subsets linked to overall survival after immunotherapy.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets